Nebula Research & Development LLC Makes New $1.62 Million Investment in United Therapeutics Co. (NASDAQ:UTHR)

Nebula Research & Development LLC acquired a new position in United Therapeutics Co. (NASDAQ:UTHR) in the fourth quarter, Holdings Channel.com reports. The firm acquired 4,584 shares of the biotechnology company’s stock, valued at approximately $1,617,000.

Several other institutional investors have also recently modified their holdings of UTHR. Lord Abbett & CO. LLC boosted its stake in United Therapeutics by 7.4% in the fourth quarter. Lord Abbett & CO. LLC now owns 216,651 shares of the biotechnology company’s stock worth $76,443,000 after buying an additional 14,956 shares in the last quarter. Hancock Whitney Corp lifted its holdings in shares of United Therapeutics by 50.0% in the 4th quarter. Hancock Whitney Corp now owns 7,708 shares of the biotechnology company’s stock worth $2,720,000 after acquiring an additional 2,569 shares during the last quarter. Voya Investment Management LLC boosted its stake in shares of United Therapeutics by 4.3% in the 4th quarter. Voya Investment Management LLC now owns 38,548 shares of the biotechnology company’s stock valued at $13,601,000 after purchasing an additional 1,581 shares in the last quarter. Integrated Wealth Concepts LLC grew its holdings in shares of United Therapeutics by 14.1% during the 4th quarter. Integrated Wealth Concepts LLC now owns 9,962 shares of the biotechnology company’s stock valued at $3,515,000 after purchasing an additional 1,230 shares during the last quarter. Finally, Syon Capital LLC purchased a new position in United Therapeutics in the 4th quarter worth $205,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Price Performance

UTHR stock opened at $291.38 on Friday. United Therapeutics Co. has a 1 year low of $233.31 and a 1 year high of $417.82. The firm has a 50-day moving average of $308.67 and a 200 day moving average of $346.55. The company has a market cap of $13.09 billion, a P/E ratio of 12.80, a PEG ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same quarter in the prior year, the company earned $4.36 EPS. On average, equities research analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on UTHR shares. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 17th. HC Wainwright reaffirmed a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. Bank of America raised shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 price target for the company in a research report on Monday, April 21st. Wells Fargo & Company restated an “equal weight” rating and issued a $314.00 price objective (down previously from $395.00) on shares of United Therapeutics in a research report on Friday. Finally, UBS Group increased their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $390.17.

Insiders Place Their Bets

In related news, Director Raymond Dwek sold 3,000 shares of the business’s stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $285.57, for a total transaction of $856,710.00. Following the sale, the director now owns 1,750 shares of the company’s stock, valued at $499,747.50. The trade was a 63.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the transaction, the executive vice president now directly owns 36,781 shares of the company’s stock, valued at $11,261,606.58. This represents a 23.02 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 84,500 shares of company stock worth $28,179,150. 11.90% of the stock is owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.